Anti-alpha5/beta1 antibody
US8350010B2 · kind B2 · utility
10Cited by
16References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2011 |
| Grant date | Jan 8, 2013 |
| Priority date | — |
| Expiry date | Jun 28, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.